Navigation Links
Peregrine Pharmaceuticals Opens Enrollment in Phase II Clinical Trial of Bavituximab in Patients with Advanced Breast Cancer
Date:1/29/2008

- New Clinical Trial Will Evaluate Anti-Tumor Activity of Bavituximab in

Combination with Docetaxel -

TUSTIN, Calif., Jan. 29 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical company developing targeted therapies for the treatment of cancer and hepatitis C virus infection (HCV), today announced that patient screening has begun in a clinical trial designed to evaluate the safety and efficacy of bavituximab in combination with chemotherapy in patients with advanced breast cancer. The primary objective of the study is to assess the overall response rate to the combination of bavituximab with docetaxel, a chemotherapy drug commonly used in advanced breast cancer. The multi-center clinical trial is being conducted in the Republic of Georgia.

In the trial's two-stage design, up to 15 patients with advanced breast cancer will be enrolled initially. The study will then be expanded up to a total of 46 patients if promising results are observed. Secondary objectives include measuring time to tumor progression, duration of response, overall patient survival and safety parameters. Patients may continue to receive bavituximab alone after completion of chemotherapy as long as the cancer does not progress and side effects are acceptable.

"We are delighted that patient screening has begun in this Phase II study that provides us with an excellent opportunity to further evaluate the potential efficacy of bavituximab in combination with chemotherapy in treating breast cancer," said Steven W. King, president and CEO of Peregrine. "This trial should allow us to build on the encouraging results we observed in breast cancer patients in an earlier bavituximab
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
2. Peregrine Reports Data Showing Bavituximabs Potential to Shrink Prostate Tumors
3. Peregrine Researchers Report Data Showing Bavituximabs Potential to Shrink Human Prostate Tumors in Model of Relapsed Disease
4. Peregrine Pharmaceuticals Submits Clinical Protocol to Initiate Bavituximab Phase II Trial in Patients With Metastatic Breast Cancer
5. Peregrine Pharmaceuticals Doses First Patient in Clinical Trial of Bavituximab in HCV Patients Co-Infected With HIV
6. Peregrine Pharmaceuticals Submits Clinical Protocol for New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer
7. New Data Confirms That a Selective, Fully Human Anti-VEGF Antibody Being Developed by Peregrine is as Effective as Avastin(R) in Preclinical Cancer Models
8. Peregrine Announces Addition of The Johns Hopkins Hospital as Study Site for Bavituximab Trial in HCV Patients Co-Infected With HIV
9. Peregrine Pharmaceuticals Receives Approval to Conduct a Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
10. Peregrine Pharmaceuticals Receives Approval to Conduct a Second Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer
11. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... the leading health care supply chain expertise, analytics and ... national contracts that expand its portfolio to provide hospital ... These include manufacturer product and service agreements, as well ... IT consulting support. New Novation agreements ...
(Date:1/15/2014)... OAKS, Calif. , Jan. 15, 2014 ... Amgen (NASDAQ: AMGN ) announced today ... jointly discover and validate new therapeutic targets and ... a chronic disorder that affects millions worldwide. The ...
(Date:1/15/2014)...  Humberto C. Antunes,  Galderma  worldwide CEO, will receive a ... of Drugs in Dermatology (JDD) at the upcoming ... is January 17-20, 2014, at the Omni Orlando Resort at ChampionsGate ... The ODAC is a distinguished event that delivers a ...
Breaking Medicine Technology:New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4
(Date:4/17/2014)... estimated that as many as 10 million older Americans ... loneliness and isolation. , However, new research a ... older Americans for six years found that Internet ... depression by more than 30 percent. , "That,s a ... University professor of telecommunication, information studies and media who ...
(Date:4/17/2014)... CHICAGO, IL, April 17, 2014-- Colic affects about one ... accounts for numerous pediatric visits during the first several ... of colic symptoms was showing promise; however, the April ... (BMJ2014;348:g2107; Sung, Valerie) reported on a study, "Probiotics ... probiotic L reuteri for infant colic ...
(Date:4/17/2014)... (BUSM) have discovered that the anti-seizure drug ezogabine, ... findings, reported in the American Journal of ... more effective treatments for alcoholism. , Excessive consumption ... of illness and death in the U.S. and ... productivity of workers and necessitating huge health care ...
(Date:4/17/2014)... researchers at UC Davis has shown that the cyclin ... cell division, also boosts the mitochondrial activity to power ... has been shown to perform both jobs. This newfound ... control cellular energy production, potentially advancing cancer care and ... the journal Developmental Cell . , "These proteins ...
(Date:4/17/2014)... international research team led by Cesar A. Arias, M.D., ... at Houston (UTHealth) has identified a new superbug that ... report appeared in the April 17 issue of ... new superbug is part of a class of highly-resistant ... MRSA, which is a major cause of hospital and ...
Breaking Medicine News(10 mins):Health News:Internet use can help ward off depression among elderly 2Health News:New study says probiotic use for infant colic is not effective in reducing symptoms 2Health News:BUSM researchers find anti-seizure drug may reduce alcohol consumption 2Health News:Dual role: Key cell division proteins also power up mitochondria 2Health News:New MRSA superbug emerges in Brazil 2
... ... Sufferers , ... March 30, 2010 -- Those with aching backs might want to look at their home ... color schemes and price range, but many don,t take time to consider products that can ...
... ... ... Tahitian Noni International (TNI) announced that their 2011 International Leadership Conference would ... of the most luxurious cruise ships in the world. The announcement was received with such ...
... ... improved longevity , ... YORK (PRWEB) March 30, 2010 -- CogniFit™, Inc., a leading maker of Brain Fitness ... longevity, author and speaker, is now an official spokesperson for CogniFit. Berg, who is ...
... ... For New Web Hosting Sign-ups , ... Vancouver, Canada (PRWEB) March 30, 2010 -- Canadian Web Hosting ( ... announced an increase of benefits for their popular affiliate program. The immediate increase from ...
... Boston University School of Medicine found that women with serum ... risk of developing gout than men. This study, the ... gout risk in women, also evaluated purported risk factors for ... and diuretic use to be among leading contributors for women. ...
... What makes some viral infections fatal and others much ... that a part of the variability can be attributed ... Professor Michael Katze, presenting at the Society for General ... modelling could be a powerful tool to allow treatments ...
Cached Medicine News:Health News:Proper Home Dcor May Assist in Alleviating Back Pain 2Health News:Proper Home Dcor May Assist in Alleviating Back Pain 3Health News:Caribbean Cruise Announced by Tahitian Noni International for 2011 2Health News:CogniFit and Longevity Expert Cooperate to Raise Awareness for the Benefits of Brain Fitness 2Health News:CogniFit and Longevity Expert Cooperate to Raise Awareness for the Benefits of Brain Fitness 3Health News:Canadian Web Hosting Increases Affiliate Incentive 2Health News:Obesity, hypertension, alcohol and diuretic use -- gout risk factors for women 2Health News:Personalizing medicine to prevent pandemics 2
... neurophysiological monitoring system has been designed ... the needs of the ever changing ... collection and analyzing data from multiple ... EMG, EEG and multiple patients at ...
... Inc. is the largest independently ... to ophthalmic surgical instrumentation. Katena ... 7,000 customers in the United ... network of distributors, to customers ...
... Studies have proven that the management of diabetes ... glucose levels is the most effective way to ... care aimed at maintaining or improving a diabetes ... and costly. , ,These have been the ...
... is intended for detecting trends and tracking ... 18 and older) and children/adolescents (aged 7 ... the use of the G2 Biographer with ... to supplement, not replace, conventional blood glucose ...
Medicine Products: